Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Avacta Group Plc
  6. Summary
    AVCT   GB00BYYW9G87

AVACTA GROUP PLC

(AVCT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
126(c) 119(c) 120(c) 122(c) 113 Last
1 711 238 1 249 059 1 302 719 680 876 1 024 600 Volume
+17.98% -5.56% +0.84% +1.67% -7.38% Change
More quotes
Estimated financial data (e)
Sales 2021 4,59 M 6,21 M 6,21 M
Net income 2021 -22,3 M -30,2 M -30,2 M
Net cash position 2021 27,8 M 37,6 M 37,6 M
P/E ratio 2021 -13,9x
Yield 2021 -
Sales 2022 4,90 M 6,64 M 6,64 M
Net income 2022 -23,5 M -31,9 M -31,9 M
Net cash position 2022 7,89 M 10,7 M 10,7 M
P/E ratio 2022 -13,3x
Yield 2022 -
Capitalization 305 M 414 M 414 M
EV / Sales 2021 60,5x
EV / Sales 2022 60,7x
Nbr of Employees 123
Free-Float 66,0%
More Financials
Company
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind... 
More about the company
Ratings of Avacta Group Plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about AVACTA GROUP PLC
09/15AVACTA : Lateral Flow Assay Testing for COVID-19 – Tackling asymptomatic spread
PU
09/09AVACTA : Notice of Results and Investor Presentation
PU
09/06AVACTA : announces new appointments to the Scientific Advisory Board of its Therapeutics D..
PU
09/06Avacta Group plc Announces New Appointments to Scientific Advisory Board
CI
09/02AVACTA : Names Chief Scientific Officer For Therapeutics Unit
MT
09/02AVACTA : Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta's Therap..
PU
09/02Avacta Group plc Appoints Fiona McLaughlin as Chief Scientific Officer of Therapeutics ..
CI
08/18Avacta Appoints Mark Goldberg as Non-Executive Director
CI
08/18AVACTA : Directorate Change
PU
08/11AVACTA : Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
BU
08/11Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
CI
08/11AVACTA : Doses First Patient In Early Stage Study Of Cancer Drug
MT
08/04AVACTA : Starts Distribution of AffiDX COVID-19 Antigen Test
MT
08/04AVACTA : Update on AffiDX« SARS-CoV-2 Antigen Lateral Flow Test
PU
08/04Avacta Group plc Provides Update on AffiDX Lateral Flow Test
CI
More news
News in other languages on AVACTA GROUP PLC
09/02Le groupe Avacta nomme un directeur scientifique pour son unité thérapeutique.
04/15LA MINUTE DURABLEá : Déforestation, marché ESG et Fukushima
02/16AVACTA GROUP PLC : bonne nouvelle pour le test antigénique SARS-CoV-2
More news
Chart AVACTA GROUP PLC
Duration : Period :
Avacta Group Plc Technical Analysis Chart | AVCT | GB00BYYW9G87 | MarketScreener
Technical analysis trends AVACTA GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 122,00 GBX
Average target price 297,50 GBX
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Alastair MacLaughlin Smith Chief Executive Officer & Executive Director
Tony Peter Gardiner Group Chief Financial Officer & Director
Eliot Richard Forster Non-Executive Chairman
Matt Johnson Chief Technology Officer
Amrik Basran Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AVACTA GROUP PLC7.02%419
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582